Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Blood (2016) 128 (5): 686–698.

https://doi.org/10.1182/blood-2016-01-693879

Published: 2016

Includes: Supplemental data

Journal Articles

High expression of lymphoid enhancer-binding factor-1 ( LEF1 ) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia

Klaus H. Metzeler, Bernhard Heilmeier, Katrin E. Edmaier, Vijay P. S. Rawat, Annika Dufour, Konstanze Döhner, Michaela Feuring-Buske, Jan Braess, Karsten Spiekermann, Thomas Büchner, Maria C. Sauerland, Hartmut Döhner, Wolfgang Hiddemann, Stefan K. Bohlander, Richard F. Schlenk, Lars Bullinger, Christian Buske

Blood (2012) 120 (10): 2118–2126.

https://doi.org/10.1182/blood-2012-02-411827

Published: 2012

Includes: Supplemental data

Journal Articles

The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

Blood (2012) 119 (19): 4383–4386.

https://doi.org/10.1182/blood-2010-12-327072

Published: 2012

Includes: Supplemental data

Journal Articles

High Expression of Lymphoid Enhancer-Binding Factor 1 ( LEF1 ) Is a Novel, Favorable Prognostic Marker in Cytogenetically Normal AML and Is Associated with Upregulation of T-Lymphoid Lineage Markers in AML Blasts.

Klaus H. Metzeler, Bernhard Heilmeier, Konstantin Petropoulos, Maria C. Sauerland, Achim Heinecke, Wolfgang E Berdel, Thomas Buechner, Jan Braess, Karsten Spiekermann, Michaela Feuring-Buske, Wolfgang Hiddemann, Stefan K Bohlander, Christian Buske

Blood (2009) 114 (22): 398.

https://doi.org/10.1182/blood.V114.22.398.398

Published: 2009

Journal Articles

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

Utz O. Krug, MD, Wolfgang Berdel, MD, Susanne Amler, Maria C. Sauerland, PhD, Bernhard Wörmann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2009) 114 (22): 998.

https://doi.org/10.1182/blood.V114.22.998.998

Published: 2009

Journal Articles

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Blood (2009) 113 (21): 5250–5253.

https://doi.org/10.1182/blood-2008-09-172668

Published: 2009

Includes: Supplemental data

Journal Articles

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

Friederike Schneider, Eva Hoster, Michael Unterhalt, Stephanie Schneider, Annika Dufour, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, Michaela Feuring-Buske, Christian Buske, Jan Braess, Achim Heinecke, Maria C. Sauerland, Wolfgang E. Berdel, Thomas Buechner, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2008) 112 (11): 2531.

https://doi.org/10.1182/blood.V112.11.2531.2531

Published: 2008

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

Journal Articles

An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups.

Klaus H. Metzeler, Manuela Hummel, Clara D. Bloomfield, Karsten Spiekermann, Maria C. Sauerland, Achim Heinecke, Michael Radmacher, Guido Marcucci, Susan P. Whitman, Kati Maharry, Peter Paschka, Richard A. Larson, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Ulrich Mansmann, Wolfgang Hiddemann, Stefan K. Bohlander, Christian Buske

Blood (2007) 110 (11): 596.

https://doi.org/10.1182/blood.V110.11.596.596

Published: 2007

Journal Articles

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Karsten Spiekermann, MD, Annika Dufour, PhD, Gudrun Mellert, Evelin Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, MD, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard Josef Wormann, MD, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Acute Myeloid Leukemia Cooperative Group (AMLCG)

Blood (2006) 108 (11): 805.

https://doi.org/10.1182/blood.V108.11.805.805

Published: 2006

Journal Articles

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Matthias Stelljes, MD, Martin Bornhaeuser, MD, Matthias Kroger, MD, Joerg Beyer, MD, Maria C. Sauerland, Achim Heinecke, PhD, Bjorna Berning, MD, Christian Scheffold, MD, Gerda Silling, MD, Thomas Buchner, MD, Andreas Neubauer, MD, Axel Arthur Fauser, MD, Gerhard Ehninger, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2006) 108 (11): 3016.

https://doi.org/10.1182/blood.V108.11.3016.3016

Published: 2006

Journal Articles

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Matthias Stelljes, Martin Bornhauser, Matthias Kroger, Joerg Beyer, Maria C. Sauerland, Achim Heinecke, Bjorna Berning, Christian Scheffold, Gerda Silling, Thomas Buchner, Andreas Neubauer, Axel A. Fauser, Gerhard Ehninger, Wolfgang E. Berdel, Joachim Kienast, for the Cooperative German Transplant Study Group

Blood (2005) 106 (9): 3314–3321.

https://doi.org/10.1182/blood-2005-04-1377

Published: 2005

Journal Articles

Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.

Blood (2004) 104 (11): 871.

https://doi.org/10.1182/blood.V104.11.871.871

Published: 2004

NARROW

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

High expression of lymphoid enhancer-binding factor-1 ( LEF1 ) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia

The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype

High Expression of Lymphoid Enhancer-Binding Factor 1 ( LEF1 ) Is a Novel, Favorable Prognostic Marker in Cytogenetically Normal AML and Is Associated with Upregulation of T-Lymphoid Lineage Markers in AML Blasts.

Continuous Decrease of Overall Survival in Patients > 30 Years of Age with Acute Myelogenous Leukemia.

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only